AnaptysBio, Inc. (ANAB)
- Previous Close
26.34 - Open
26.76 - Bid 26.43 x 100
- Ask 26.61 x 200
- Day's Range
25.69 - 27.02 - 52 Week Range
13.36 - 27.50 - Volume
326,029 - Avg. Volume
360,767 - Market Cap (intraday)
726.128M - Beta (5Y Monthly) -0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-6.08 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
45.44
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
www.anaptysbio.comRecent News: ANAB
Performance Overview: ANAB
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANAB
Valuation Measures
Market Cap
726.13M
Enterprise Value
353.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
41.71
Price/Book (mrq)
8.24
Enterprise Value/Revenue
20.58
Enterprise Value/EBITDA
-2.47
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.47%
Return on Equity (ttm)
-93.44%
Revenue (ttm)
17.16M
Net Income Avi to Common (ttm)
-163.62M
Diluted EPS (ttm)
-6.08
Balance Sheet and Cash Flow
Total Cash (mrq)
390.9M
Total Debt/Equity (mrq)
373.00%
Levered Free Cash Flow (ttm)
-73.42M